FGFR1 and neoplasm: Another TKI (lenvatinib) can decrease tumor vascular permeability and inhibit tumor neovessel maturation and assembly through targeting VEGFR1–3, fibroblast growth factor receptor (FGFR)1–4, PDGFR-α, c-Kit protein, and RET protein.